TNhYP218 CAR T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TNhYP218 CAR T cells, covering 2026-02-17 to 2026-02-17. Get the full timeline:
Most recent: Clinical Trial Update: Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma [Phase 1]